# US 2026/0097093 A1 · Targeted amatoxin conjugate for the treatment of solid tumors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097093 A1
- Document ID: US20260097093A1
- Status: Published application
- Kind: A1
- Application number: 19/350,762
- Filed: 2025-10-06
- Published: 2026-04-09
- Earliest claimed: 2018-04-13
- Assignees: Heidelberg Pharma Research GmbH
- Applicants: Heidelberg Pharma Research GmbH
- Inventors: Christoph Müller; Werner Simon; Christian Lutz; Susanne Werner-Simon; Torsten Hechler; Michael Kulke; Andreas Pahl
- Web page: https://patentgrep.com/patent/US20260097093A1

## CPC

- A61K 38/12: Cyclic peptides {, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C (A61K38/043 - A61K38/046 take precedence)}
- A61K 47/65: Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A61K 47/6831: {Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin}
- A61K 47/6855: {the tumour determinant being from breast cancer cell}
- A61K 47/6867: {the tumour determinant being from a cell of a blood cancer}
- A61K 47/6869: {the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate}
- A61K 47/6871: {the antibody targeting an enzyme}
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An amatoxin-linker construct contains an amatoxin according to formula (I) wherein R1 and R2 are each —OH, R3 is NH2, or a linker which carries a reactive group Y for linking said amatoxin to a target-binding moiety, R4 is H or a linker which carries a reactive group Y for linking said amatoxin to a target-binding moiety, R5 is absent or ═O, and wherein R3 and R4 cannot be the same. The amatoxin-linker construct is used in the manufacture of a binding moiety-toxin conjugate for the treatment of a solid tumor, and a respective binding moiety-toxin conjugate can be used for the treatment of a solid tumor.

## Claims

### Claim 1

A method of treating a patient afflicted with a solid tumor, the method comprising:
administering to said patient an effective amount of a binding moiety-toxin conjugate,
wherein the binding moiety-toxin conjugate comprises an amatoxin-linker construct selected from the group consisting of:
and
wherein said solid tumor is resistant to a binding moiety-toxin conjugate whose amatoxin according to formula (I) does not comprise an —OR4 substituent at 6′-position of the indol, wherein formula (I) is defined as
and wherein
R1 and R2 are each —OH,
R3 is NH2, or a linker which carries a reactive group Y for linking said amatoxin to a target-binding moiety,
R4 is H or a linker which carries a reactive group Y for linking said amatoxin to a target-binding moiety,
R5 is absent or =0,
wherein R3 and R4 cannot be the same, and
wherein the target-binding moiety is an antibody, antibody fragment, antibody-based binding protein, or an antibody mimetic, all of which retain target binding properties.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said target-binding moiety binds at least one target selected from the group consisting of Her2, and PSMA.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the solid tumor is at least one selected from the group consisting of (a) sarcoma, (b) blastoma, and (c) carcinoma.

### Claim 4 (depends on 1)

The method according to claim 1, wherein said target-binding moiety comprises an antibody or fragment or a derivative thereof which comprises an engineered cysteine residue.

### Claim 5 (depends on 4)

The method according to claim 4, wherein said cysteine residue is selected from the group consisting of heavy chain 118Cys, heavy chain 239Cys, and heavy chain 265Cys, according to the EU numbering system.
